Mineralys reports $198.2M cash position funding operations through Q1 2026, with pivotal hypertension trial data expected in early 2025. R&D investment signals growth.

– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1…...

Mineralys shares surged 86% after AstraZeneca announced positive Phase 3 results for its similar blood pressure drug, Baxdrostat. "The results seem slightly worse than Mineralys' Lorundrostat," accord...

Biotech firm Mineralys Therapeutics announces $175M common stock offering with $26.25M additional option. Proceeds to fund lorundrostat clinical development for hypertension and CKD treatment.

Using AI to find stock market opportunities.

Amazingly Simple Graphic Design Software – Canva

Mineralys prices 13M shares at $13.50 each to advance lorundrostat clinical trials. Major investment banks back the offering to fund drug development and commercialization efforts.

Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025

In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors

Get more from THE OPTIONS BULLY on Patreon

Get more from THE OPTIONS BULLY on Patreon

YouTube video by Christina Talks

Mineralys Therapeutics (Nasdaq: MLYS) reported Q3 2025 results and a corporate update on Nov 10, 2025. Key clinical milestones include a planned NDA submission for lorundrostat in late‑2025 or Q1 2026 and completed enrollment in the Explore‑OSA Phase 2 trial with topline data expected Q1 2026.Financial highlights: $593.6M cash, cash equivalents and investments as of Sep 30, 2025 (vs. $198.2M at Dec 31, 2024), and a completed public equity financing raising approximately $287.5M gross on Sep 4, 2025. Q3 net loss was $36.9M; R&D expense was $31.5M (Q3 2024: $54.0M). Management expects cash to fund operations into 2028.